Deepak Hegde
Founding Director, Endless Frontier Labs Professor of Management
NYU Stern School of Business

Welcome to Frontiers 2022!

At the Endless Frontier Labs, our mission is to accelerate the success of science and technology-based startups. We pursue this mission through a nine-month, zero-fee mentoring program for Seed-stage startups selected from all over the world. While societal progress
is the true touchstone of our performance, EFL startups are distinguishing themselves as exceptional based on every metric of early-stage ventures’ success. For example, since 2019, sixty-four of our Seed-stage program graduates have successfully closed their financing rounds and have collectively raised over $900M in funding. These startups are deploying their innovations in fields ranging from gene editing and drug development through communications and machine learning towards improving human productivity and well-being.

Frontiers 2022 will showcase the 52 startup graduates of our 2021-22 cohort to investors, industry participants, and other partners in our ecosystem. Consistent with our goal for this showcase event to serve as a platform to view the frontiers of progress, we have organized startup presentations into focus areas such as oncology, immunotherapy, mental health, enterprise platforms, IoT, cloud computing, and more. Our startup graduates have made progress in these areas through the commitment of our extraordinary community of mentors, scientists, and corporate partners, who over the past nine months have dedicated their invaluable attention to our mission. Throughout Frontiers 2022, our mentors will highlight the promise of our startups and provide insights on science, technology, and industry trends.

We invite you to get to know the EFL graduates as they continue to look for advice, connections, and investments in their journeys ahead. If you would like to stay connected with the EFL community after Frontiers 2022, please email us at info@endlessfrontierlabs.com. We look forward to hearing from you.

On behalf of the EFL team, I wish you an engaging and fulfilling Frontiers 2022.

DAY 1: LIFE SCIENCES & HEALTH-TECH

MAY 5, 2022 – 10a – 6p ET

Day 1 will feature EFL startups with innovations in pharmaceuticals, biology, medical devices, and information technologies to help improve human health outcomes.

Day 1 Schedule

Oncology

Novel platforms, modalities and therapeutics for combating a variety of cancer types.

    Startups:

  • myNEO
  • Alixia
  • Lime Therapeutics
  • Reveal Pharma
  • Cytosolix

View startup details here

Cell, Gene, and Immunotherapies

Therapies that harness the power of biological response to treat, cure, or prevent cancers and other diseases.

    Startups:

  • RenBio
  • Immunyx Pharma
  • Celestial Therapeutics
  • Entelexo Biotherapeutics
  • Myosin Therapeutics
  • MarPam Pharma

View startup details here

Panel: Trends in Life Sciences and Healthcare

Join us for a panel discussion with EFL alumni founders and academic scientists who are shaping the frontiers of life sciences and healthcare development. The wide-ranging conversation will span topics such as cutting-edge scientific advances and their implications for commercialization, the challenges faced by life sciences startups, the post-pandemic industry landscape, mental health, healthcare access, and more.

    Panelists:

  • Rana Al-Hallaq, Executive Director and Partner, Pfizer Ventures & EFL Chief Mentor, Life Sciences
  • Grace Chang, CEO & Co-founder, Kintsugi, EFL Alum 2021
  • Martina Roos, CEO & Co-founder, Sardona Therapeutics, EFL Alum 2021
  • Noam Solomon, CEO & Co-founder, Immunai, EFL Alum 2020
  • Jacob Becraft, Co-founder & CEO, Strand Therapeutics, EFL Alum 2019
Devices and MedTech

Devices and technologies for medical and surgical applications and for diagnosing or treating conditions spanning diabetes, kidney failure, spinal cord injury, medical and surgical applications, and more.

    Startups:

  • Matricelf
  • Ommo Technologies
  • Qidni Labs
  • Isla Technologies

View startup details here

Neuroscience and Mental Health

Biology, hardware and software innovations to improve the diagnosis and treatment of neurological and mental health conditions.

    Startups:

  • TRIPP
  • Polaris Genomics
  • Cordance Medical
  • Spark Neuro

View startup details here

Computational and Synthetic Biology

Platforms that apply AI/ML tools, computer vision, and engineering design principles to identify novel, effective medications.

    Startups:

  • Wild Biotech
  • OncoPrecision
  • Waypoint Bio
  • Interface Biosciences
  • imvaria
  • Inherent Biosciences
  • Think Bioscience

View startup details here

Fireside Chat with Sharon Mates, Founder, Chairman and CEO, Intra-Cellular Therapies & EFL Chief Mentor, Life Sciences

As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company developing novel treatments that harness Nobel-prize winning science that broadens the way scientists understand how therapeutics affect the intra-cellular signaling of neurons and other cells. This vital work helps drive the development of new treatments for schizophrenia and other neuropsychiatric conditions.

Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.

Dr. Mates received her B.S from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

DAY 2: DATA & DEEP TECH

MAY 6, 2022 – 10a – 6p ET

Day 2 will feature EFL startups using novel information and communication technologies, materials, and advanced manufacturing techniques to improve the productivity of a variety of consumer and industrial applications.

Day 2 Schedule

Sustainable Solutions

New materials and techniques that seek to reduce our dependence on natural resources.

    Startups:

  • Sundial Foods
  • ARC Marine
  • Metaseismic
  • Natrion

View startup details here

Chemical Engineering & Materials

New technologies that improve chemical products and processes.

    Startups:

  • EV Biotech
  • Cirona Labs
  • Sunthetics
  • Detrapel

View startup details here

Web3 and the Metaverse

Novel applications of blockchain and augmented reality to manage decentralized or user-based interactions.

    Startups:

  • Kinetix
  • DODO
  • Chainstarters
  • Veracity Protocol
  • Spiral Technology
  • Dreamworld

View startup details here

Panel: The Future of Tech

Join us for a panel discussion of EFL alumni and technologists who are catalyzing the next Industrial Revolution. Panelists will discuss emerging technologies, including advances in AI, ML, quantum computing, IoT, blockchain, and materials science.

    Panelists:

  • Erik Nordlander, General Partner, GV & EFL Mentor, Deep Tech
  • Foster Provost, Scientist at Compass and Prof. of Entrepreneurship, Data Science, and Information Systems at NYU Stern
  • Christina Qi, Co-founder & CEO, Databento, EFL Alum 2021
  • Luciano Bueno, CEO & Co-founder, GALY, EFL Alum 2021
  • Laura Kornhauser, CEO & Co-founder, Stratyfy, EFL Alum 2020
  • Saoud Khalifah, CEO , CTO, & Co-founder, Fakespot, EFL Alum 2019
Enterprise Platforms

Data and AI-driven solutions improving the productivity of enterprise applications across finance, marketing, communications, and enterprise resource planning.

    Startups:

  • Enduvo
  • Oblivious
  • Pagedip
  • Blu Sphinx
  • Adaptive Investment Solutions
  • Corral Data
  • SlyceData

View startup details here

IoT and Cloud Computing


Advanced communication technologies with applications in web infrastructure, supply chain management, and connectivity.

    Startups:

  • Shabodi
  • Bridgefy
  • Webee
  • Unum ID
  • ZaiNar

View startup details here

Fireside Chat with Kevin Ryan, Founder and CEO, AlleyCorp & EFL Advisor

Kevin P. Ryan is one of the leading Internet entrepreneurs in New York, having founded and is Chairman of several businesses, including AlleyCorp, Zola and Nomad Health. Previously he founded and was Chairman of MongoDB, Business Insider and GILT. Combined, these companies have raised more than $700 million in venture capital funding and currently employ almost 2,000 people. Previously, Kevin helped build DoubleClick from 1996 to 2005, first as President and later as CEO. He led DoubleClick’s growth from a 20-person startup to a publicly traded global leader with over 1,500 employees. In 2013, Kevin was named one of “The 100 Most Influential New Yorkers of the Past 25 Years” by the Observer.

Aside from his professional responsibilities, Kevin serves on the board of Mercy Corps, is Vice Chairman of The Partnership for New York City, is a member of the CFR Committee on Foreign Affairs, is on the Board of TECH:NYC and is Director Emeritus for Human Right Watch. He previously served on the boards of Yale Corporation, INSEAD, the Direct Marketing Association, The Ad Council, HotJobs and the advisory board of Doctors Without Borders. He holds a B.A. from Yale University and an M.B.A. from INSEAD.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

Welcome to Frontiers 2022!

At the Endless Frontier Labs, our mission is to accelerate the success of science and technology-based startups. We pursue this mission through a nine-month, zero-fee mentoring program for Seed-stage startups selected from all over the world. While societal progress is the true touchstone of our performance, EFL startups are distinguishing themselves as exceptional based on every metric of early-stage ventures’ success. For example, since 2019, sixty-four of our Seed-stage program graduates have successfully closed their financing rounds and have collectively raised over $900M in funding. These startups are deploying their innovations in fields ranging from gene editing and drug development through communications and machine learning towards improving human productivity and well-being.

Frontiers 2022 will showcase the 52 startup graduates of our 2021-22 cohort to investors, industry participants, and other partners in our ecosystem. Consistent with our goal for this showcase event to serve as a platform to view the frontiers of progress, we have organized startup presentations into focus areas such as oncology, immunotherapy, mental health, enterprise platforms, IoT, cloud computing, and more. Our startup graduates have made progress in these areas through the commitment of our extraordinary community of mentors, scientists, and corporate partners, who over the past nine months have dedicated their invaluable attention to our mission. Throughout Frontiers 2022, our mentors will highlight the promise of our startups and provide insights on science, technology, and industry trends.

We invite you to get to know the EFL graduates as they continue to look for advice, connections, and investments in their journeys ahead. If you would like to stay connected with the EFL community after Frontiers 2022, please email us at info@endlessfrontierlabs.com. We look forward to hearing from you.

On behalf of the EFL team, I wish you an engaging and fulfilling Frontiers 2022.

Deepak Hegde

Founding Director, Endless Frontier Labs Professor of Management
NYU Stern School of Business

DAY 1: LIFE SCIENCES & HEALTH-TECH

MAY 5, 2022 – 10a – 6p ET

 


Day 1 will feature EFL startups with innovations in pharmaceuticals, biology, medical devices, and information technologies to help improve human health outcomes.

Day 1 Schedule

Oncology

Novel platforms, modalities and therapeutics for combating a variety of cancer types.

    Startups:

  • myNEO
  • Alixia
  • Lime Therapeutics
  • Reveal Pharma
  • Cytosolix

View startup details here

Cell, Gene, and Immunotherapies

Therapies that harness the power of biological response to treat, cure, or prevent cancers and other diseases.

    Startups:

  • RenBio
  • Immunyx Pharma
  • Celestial Therapeutics
  • Entelexo Biotherapeutics
  • Myosin Therapeutics
  • MarPam Pharma

View startup details here

Panel: Trends in Life Sciences and Healthcare

Join us for a panel discussion with EFL alumni founders and academic scientists who are shaping the frontiers of life sciences and healthcare development. The wide-ranging conversation will span topics such as cutting-edge scientific advances and their implications for commercialization, the challenges faced by life sciences startups, the post-pandemic industry landscape, mental health, healthcare access, and more.

    Panelists:

  • Rana Al-Hallaq, Executive Director and Partner, Pfizer Ventures & EFL Chief Mentor, Life Sciences
  • Grace Chang, CEO & Co-founder, Kintsugi, EFL Alum 2021
  • Martina Roos, CEO & Co-founder, Sardona Therapeutics, EFL Alum 2021
  • Noam Solomon, CEO & Co-founder, Immunai, EFL Alum 2020
  • Jacob Becraft, Co-founder & CEO, Strand Therapeutics, EFL Alum 2019
Devices and MedTech

Devices and technologies for medical and surgical applications and for diagnosing or treating conditions spanning diabetes, kidney failure, spinal cord injury, medical and surgical applications, and more.

    Startups:

  • Matricelf
  • Ommo Technologies
  • Qidni Labs
  • Isla Technologies

View startup details here

Neuroscience and Mental Health

Biology, hardware and software innovations to improve the diagnosis and treatment of neurological and mental health conditions.

    Startups:

  • TRIPP
  • Polaris Genomics
  • Cordance Medical
  • Spark Neuro

View startup details here

Computational and Synthetic Biology

Platforms that apply AI/ML tools, computer vision, and engineering design principles to identify novel, effective medications.

    Startups:

  • Wild Biotech
  • OncoPrecision
  • Waypoint Bio
  • Interface Biosciences
  • imvaria
  • Inherent Biosciences
  • Think Bioscience

View startup details here

Fireside Chat with Sharon Mates, Founder, Chairman and CEO, Intra-Cellular Therapies & EFL Chief Mentor, Life Sciences

As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company developing novel treatments that harness Nobel-prize winning science that broadens the way scientists understand how therapeutics affect the intra-cellular signaling of neurons and other cells. This vital work helps drive the development of new treatments for schizophrenia and other neuropsychiatric conditions.

Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.

Dr. Mates received her B.S from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

DAY 2: DATA & DEEP TECH

MAY 6, 2022 – 10a – 6p ET

 

Day 2 will feature EFL startups using novel information and communication technologies,materials, and advanced manufacturing techniques to improve the productivity of a variety of consumer and industrial applications.

Day 2 Schedule

Sustainable Solutions

New materials and techniques that seek to reduce our dependence on natural resources.

    Startups:

  • Sundial Foods
  • ARC Marine
  • Metaseismic
  • Natrion

View startup details here

Chemical Engineering & Materials

New technologies that improve chemical products and processes.

    Startups:

  • EV Biotech
  • Cirona Labs
  • Sunthetics
  • Detrapel

View startup details here

Web3 and the Metaverse

Novel applications of blockchain and augmented reality to manage decentralized or user-based interactions.

    Startups:

  • Kinetix
  • DODO
  • Chainstarters
  • Veracity Protocol
  • Spiral Technology
  • Dreamworld

View startup details here

Panel: The Future of Tech

Join us for a panel discussion of EFL alumni and technologists who are catalyzing the next Industrial Revolution. Panelists will discuss emerging technologies, including advances in AI, ML, quantum computing, IoT, blockchain, and materials science.

    Panelists:

  • Erik Nordlander, General Partner, GV & EFL Mentor, Deep Tech
  • Foster Provost, Scientist at Compass and Prof. of Entrepreneurship, Data Science, and Information Systems at NYU Stern
  • Christina Qi, Co-founder & CEO, Databento, EFL Alum 2021
  • Luciano Bueno, CEO & Co-founder, GALY, EFL Alum 2021
  • Laura Kornhauser, CEO & Co-founder, Stratyfy, EFL Alum 2020
  • Saoud Khalifah, CEO , CTO, & Co-founder, Fakespot, EFL Alum 2019
Enterprise Platforms

Data and AI-driven solutions improving the productivity of enterprise applications across finance, marketing, communications, and enterprise resource planning.

    Startups:

  • Enduvo
  • Oblivious
  • Pagedip
  • Blu Sphinx
  • Adaptive Investment Solutions
  • Corral Data
  • SlyceData

View startup details here

IoT and Cloud Computing


Advanced communication technologies with applications in web infrastructure, supply chain management, and connectivity.

    Startups:

  • Shabodi
  • Bridgefy
  • Webee
  • Unum ID
  • ZaiNar

View startup details here

Fireside Chat with Kevin Ryan, Founder and CEO, AlleyCorp & EFL Advisor

Kevin P. Ryan is one of the leading Internet entrepreneurs in New York, having founded and is Chairman of several businesses, including AlleyCorp, Zola and Nomad Health. Previously he founded and was Chairman of MongoDB, Business Insider and GILT. Combined, these companies have raised more than $700 million in venture capital funding and currently employ almost 2,000 people. Previously, Kevin helped build DoubleClick from 1996 to 2005, first as President and later as CEO. He led DoubleClick’s growth from a 20-person startup to a publicly traded global leader with over 1,500 employees. In 2013, Kevin was named one of “The 100 Most Influential New Yorkers of the Past 25 Years” by the Observer.

Aside from his professional responsibilities, Kevin serves on the board of Mercy Corps, is Vice Chairman of The Partnership for New York City, is a member of the CFR Committee on Foreign Affairs, is on the Board of TECH:NYC and is Director Emeritus for Human Right Watch. He previously served on the boards of Yale Corporation, INSEAD, the Direct Marketing Association, The Ad Council, HotJobs and the advisory board of Doctors Without Borders. He holds a B.A. from Yale University and an M.B.A. from INSEAD.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

Deepak Hegde

Founding Director, Endless Frontier Labs Professor of Management
NYU Stern School of Business

FRONTIERS 2022

At the Endless Frontier Labs, our mission is to accelerate the success of science and technology-based startups. We pursue this mission through a nine-month, zero-fee mentoring program for Seed-stage startups selected from all over the world. While societal progress is the true touchstone of our performance, EFL startups are distinguishing themselves as exceptional based on every metric of early-stage ventures’ success. For example, since 2019, sixty-four of our Seed-stage program graduates have successfully closed their financing rounds and have collectively raised over $900M in funding. These startups are deploying their innovations in fields ranging from gene editing and drug development through communications and machine learning towards improving human productivity and well-being.

Frontiers 2022 will showcase the 52 startup graduates of our 2021-22 cohort to investors, industry participants, and other partners in our ecosystem. Consistent with our goal for this showcase event to serve as a platform to view the frontiers of progress, we have organized startup presentations into focus areas such as oncology, immunotherapy, mental health, enterprise platforms, IoT, cloud computing, and more. Our startup graduates have made progress in these areas through the commitment of our extraordinary community of mentors, scientists, and corporate partners, who over the past nine months have dedicated their invaluable attention to our mission. Throughout Frontiers 2022, our mentors will highlight the promise of our startups and provide insights on science, technology, and industry trends.

We invite you to get to know the EFL graduates as they continue to look for advice, connections, and investments in their journeys ahead. If you would like to stay connected with the EFL community after Frontiers 2022, please email us at info@endlessfrontierlabs.com. We look forward to hearing from you.

On behalf of the EFL team, I wish you an engaging and fulfilling Frontiers 2022.

DAY 1: LIFE SCIENCES & HEALTH-TECH

MAY 5, 2022 – 10a – 6p ET


Day 1 will feature EFL startups with innovations in pharmaceuticals, biology, medical devices, and information technologies to help improve human health outcomes.

Day 1 Schedule

Oncology

Novel platforms, modalities and therapeutics for combating a variety of cancer types.

    Startups:

  • myNEO
  • Alixia
  • Lime Therapeutics
  • Reveal Pharma
  • Cytosolix

View startup details here

Cell, Gene, and Immunotherapies

Therapies that harness the power of biological response to treat, cure, or prevent cancers and other diseases.

    Startups:

  • RenBio
  • Immunyx Pharma
  • Celestial Therapeutics
  • Entelexo Biotherapeutics
  • Myosin Therapeutics
  • MarPam Pharma

View startup details here

Panel: Trends in Life Sciences and Healthcare

Join us for a panel discussion with EFL alumni founders and academic scientists who are shaping the frontiers of life sciences and healthcare development. The wide-ranging conversation will span topics such as cutting-edge scientific advances and their implications for commercialization, the challenges faced by life sciences startups, the post-pandemic industry landscape, mental health, healthcare access, and more.

    Panelists:

  • Rana Al-Hallaq, Executive Director and Partner, Pfizer Ventures & EFL Chief Mentor, Life Sciences
  • Grace Chang, CEO & Co-founder, Kintsugi, EFL Alum 2021
  • Martina Roos, CEO & Co-founder, Sardona Therapeutics, EFL Alum 2021
  • Noam Solomon, CEO & Co-founder, Immunai, EFL Alum 2020
  • Jacob Becraft, Co-founder & CEO, Strand Therapeutics, EFL Alum 2019
Devices and MedTech

Devices and technologies for medical and surgical applications and for diagnosing or treating conditions spanning diabetes, kidney failure, spinal cord injury, medical and surgical applications, and more.

    Startups:

  • Matricelf
  • Ommo Technologies
  • Qidni Labs
  • Isla Technologies

View startup details here

Neuroscience and Mental Health

Biology, hardware and software innovations to improve the diagnosis and treatment of neurological and mental health conditions.

    Startups:

  • TRIPP
  • Polaris Genomics
  • Cordance Medical
  • Spark Neuro

View startup details here

Computational and Synthetic Biology

Platforms that apply AI/ML tools, computer vision, and engineering design principles to identify novel, effective medications.

    Startups:

  • Wild Biotech
  • OncoPrecision
  • Waypoint Bio
  • Interface Biosciences
  • imvaria
  • Inherent Biosciences
  • Think Bioscience

View startup details here

Fireside Chat with Sharon Mates, Founder, Chairman and CEO, Intra-Cellular Therapies & EFL Chief Mentor, Life Sciences

As Founder, Chairman and CEO of Intra-Cellular Therapies (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company developing novel treatments that harness Nobel-prize winning science that broadens the way scientists understand how therapeutics affect the intra-cellular signaling of neurons and other cells. This vital work helps drive the development of new treatments for schizophrenia and other neuropsychiatric conditions.

Dr. Mates has more than 25 years of experience leading public and private companies with a steadfast commitment to cutting-edge science and research to discover innovative approaches to treating disease. Prior to co-founding ITCI in 2002, she was President and board member of North American Vaccine Inc. and its predecessor companies for almost a decade, during which time she oversaw the development and approval of pediatric vaccines. Throughout her career, she has held numerous advisory and board positions including a current board appointment to Biotechnology Innovation Organization Emerging Company Section (BIO ECS). Previous appointments include chairman of the New York Biotechnology Association, Board of Visitors of the Biotechnology Institute of the University of Maryland, and member of the Harvard School of Public Health Advisory Council of the Center for Society and Health.

Dr. Mates received her B.S from The Ohio State University and her Ph.D. from the University of Washington. She completed her postdoctoral fellowships at the Massachusetts General Hospital and Harvard Medical School.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

DAY 2: DATA & DEEP TECH

MAY 6, 2022 – 10a – 6p ET


Day 2 will feature EFL startups using novel information and communication technologies, materials, and advanced manufacturing techniques to improve the productivity of a variety of consumer and industrial applications.

Day 2 Schedule

Sustainable Solutions

New materials and techniques that seek to reduce our dependence on natural resources.

    Startups:

  • Sundial Foods
  • ARC Marine
  • Metaseismic
  • Natrion

View startup details here

Chemical Engineering & Materials

New technologies that improve chemical products and processes.

    Startups:

  • EV Biotech
  • Cirona Labs
  • Sunthetics
  • Detrapel

View startup details here

Web3 and the Metaverse

Novel applications of blockchain and augmented reality to manage decentralized or user-based interactions.

    Startups:

  • Kinetix
  • DODO
  • Chainstarters
  • Veracity Protocol
  • Spiral Technology
  • Dreamworld

View startup details here

Panel: The Future of Tech

Join us for a panel discussion of EFL alumni and technologists who are catalyzing the next Industrial Revolution. Panelists will discuss emerging technologies, including advances in AI, ML, quantum computing, IoT, blockchain, and materials science.

    Panelists:

  • Erik Nordlander, General Partner, GV & EFL Mentor, Deep Tech
  • Foster Provost, Scientist at Compass and Prof. of Entrepreneurship, Data Science, and Information Systems at NYU Stern
  • Christina Qi, Co-founder & CEO, Databento, EFL Alum 2021
  • Luciano Bueno, CEO & Co-founder, GALY, EFL Alum 2021
  • Laura Kornhauser, CEO & Co-founder, Stratyfy, EFL Alum 2020
  • Saoud Khalifah, CEO , CTO, & Co-founder, Fakespot, EFL Alum 2019
Enterprise Platforms

Data and AI-driven solutions improving the productivity of enterprise applications across finance, marketing, communications, and enterprise resource planning.

    Startups:

  • Enduvo
  • Oblivious
  • Pagedip
  • Blu Sphinx
  • Adaptive Investment Solutions
  • Corral Data
  • SlyceData

View startup details here

IoT and Cloud Computing


Advanced communication technologies with applications in web infrastructure, supply chain management, and connectivity.

    Startups:

  • Shabodi
  • Bridgefy
  • Webee
  • Unum ID
  • ZaiNar

View startup details here

Fireside Chat with Kevin Ryan, Founder and CEO, AlleyCorp & EFL Advisor

Kevin P. Ryan is one of the leading Internet entrepreneurs in New York, having founded and is Chairman of several businesses, including AlleyCorp, Zola and Nomad Health. Previously he founded and was Chairman of MongoDB, Business Insider and GILT. Combined, these companies have raised more than $700 million in venture capital funding and currently employ almost 2,000 people. Previously, Kevin helped build DoubleClick from 1996 to 2005, first as President and later as CEO. He led DoubleClick’s growth from a 20-person startup to a publicly traded global leader with over 1,500 employees. In 2013, Kevin was named one of “The 100 Most Influential New Yorkers of the Past 25 Years” by the Observer.

Aside from his professional responsibilities, Kevin serves on the board of Mercy Corps, is Vice Chairman of The Partnership for New York City, is a member of the CFR Committee on Foreign Affairs, is on the Board of TECH:NYC and is Director Emeritus for Human Right Watch. He previously served on the boards of Yale Corporation, INSEAD, the Direct Marketing Association, The Ad Council, HotJobs and the advisory board of Doctors Without Borders. He holds a B.A. from Yale University and an M.B.A. from INSEAD.

Elizabeth Elting Fund Award

The EFL Elizabeth Elting Fund
invests in women-led startups that advance human welfare through science and technology.

Elizabeth Elting is an American businesswoman, entrepreneur, and philanthropist. She graduated from the Stern School of Business at New York University and is the Founder and CEO of the Elizabeth Elting Foundation. She previously co-founded TransPerfect, the world’s largest provider of language and business solutions, which has over $1.1B in revenues and more than 6,000 employees in over 100 cities around the globe. She has been recognized for her outstanding entrepreneurship and focus on developing women business leaders. Learn more about the award here.

Elite Mentors

 

“I think the EFL Program is terrific. What makes it so terrific is the mix of resources that are available to entrepreneurs.”

 

Sharon Mates

Founder, Chairman and CEO, Intra-Cellular Therapies

 


“The founders that we meet are really great technologists and scientists which is one of the reasons why we get excited to spend time with them.

Sashi Reddi

Founder and Managing Partner, SRI Capital

 


“The NYU Stern association is a real added value, MBA students can bring perspectives founders don’t even know they are missing. Founders I have spoken to have been thrilled with the MBA participation.

Arthur Klausner

President and CEO, Goldilocks Therapeutics

 


“I haven’t been in an environment where high-quality operators, investors, and scientists regularly come together. It’s a powerful mix at EFL.

Bill O’Farrell

Co-Founder Body Labs, SpeechWorks, and OpenAir.com

 


“Being a founder is really hard; it requires strength, perseverance, and grit. To be part of a community like EFL is deeply important for early-stage founders.

Maggie Sprenger

Managing Director, Green Cow Venture Capital

 


“I think EFL has an interesting structure and I really appreciate the business aspect coming together with the science and technical aspect. EFL offers many features that other programs don’t have.

Rana All-Hallaq

Senior Director and Principal, Pfizer Ventures

 

ENDLESS FRONTIER LABS MISSION

To transform breakthrough science into societal impact. We seek to advance human welfare by supporting founders of science and technology-based startups.

ENDLESS FRONTIER LABS PROGRAM

Founded at New York University’s Stern School of Business, Endless Frontier Labs guides founders through a performance-based mentoring process over the course of nine months. Endless Frontier Labs is open to pre-Series A science and technology startups. The program is suitable for founders from around the world seeking connections to the thriving New York startup ecosystem or U.S. markets. Founders are not required to have a New York University affiliation and do not have to relocate to New York. The program is completely free for participating founders and does not take any equity in startups.

EFL Partners

EFL is supported by the program’s principal founding partner Stewart Satter and founding partner William R. Berkley. EFL’s corporate partners support the program and its participating startups through a variety of services.


SPECIAL GUESTS AND SPEAKERS

Raghu Sundaram

Dean, Leonard N. Stern School of Business

Sharon Mates

Founder, Chairman and CEO, Intra-Cellular Therapies & EFL Chief Mentor, Life Sciences

Kevin Ryan

Co-Founder and Chairman, AlleyCorp & EFL Advisor

Elizabeth Elting

Founder and CEO, Elizabeth Elting Foundation & Stern MBA ‘92

Rana Al-Hallaq

Executive Director and Partner, Pfizer Ventures & EFL Chief Mentor, Life Sciences

Foster Provost

Scientist at Compass and Prof. of Entrepreneurship, Data Science, and Information Systems at NYU Stern

Erik Nordlander

General Partner, GV & EFL Mentor, Deep Tech

Christina Qi

Co-founder & CEO, Databento, EFL Alum 2021

Grace Chang

CEO & Co-founder, Kintsugi, EFL Alum 2021

Martina Roos

CEO & Co-founder, Sardona Therapeutics, EFL Alum 2021

Luciano Bueno

CEO & Co-founder, GALY, EFL Alum 2021

Noam Solomon

CEO & Co-founder, Immunai, EFL Alum 2020

Laura Kornhauser

CEO & Co-founder, Stratyfy, EFL Alum 2020

Saoud Khalifah

CEO , CTO, & Co-founder, Fakespot, EFL Alum 2019

Jake Becraft

Co-founder & CEO, Strand Therapeutics, EFL Alum 2019


2021-22 GRADUATES


Adaptive Investment Solutions

FUNDRAISING

Adaptive levels the playing field for investors and advisors by simplifying portfolio solutions using downside protection and tax-smart rebalancing otherwise a province of ultra high-net-worth clients.

Aequor

FUNDRAISING

Aequor remediates bacterial and fungal biofilm and biofouling with proprietary “green” chemical formulations for agro-industrial verticals including biofuel production and water treatments. Our PFAS remediation and surface cleaners control antimicrobial-resistant (AMR) bacteria and fungi saving customers time, energy, water, and manpower.

AiRANACULUS

AiRANACULUS is developing an intelligent radio frequency software solution to optimize wireless networks in high interference environments with spectrum aware technologies that re-configure radio and sensor systems for optimal performance.

Alixia

FUNDRAISING

Alixia is a platform therapeutics company that targets tumor heterogeneity. Our platform integrates developmental biology, biophysics and computational biology to identify molecules that disrupt the metabolic and inflammatory triggers within the tumor, enabling effective and durable cancer treatments.

Amplified Sciences

FUNDRAISING

Amplified Sciences is a clinical stage in vitro diagnostics company that accurately detects debilitating diseases sooner, starting with pancreatic cancer, by using a portfolio of fully integrated point-of-care assays that minimize sample volumes.

ARC Marine

ARC Marine is eco-engineering low carbon, nature based, and nontoxic building solutions that rehabilitates damaged marine habitats. Its patented technology is disrupting offshore construction activities by challenging traditional materials and shifting mindsets about how we integrate marine conservation into standard construction projects.

AUAR

FUNDRAISING

Automated Architecture (AUAR) is revolutionizing affordable housing by building a distributed manufacturing network for net-zero timber housing using patent-pending robotic systems, powered by a digital supply chain.

Azarc

FUNDRAISING

Azarc is developing a software, Verathread®, that improves B2B workflow efficiency by enabling data sharing and transaction capabilities across disconnected and competitive systems.

Bankuish

FUNDRAISING

Bankuish brings dignity to the financial lives of gig workers and freelancers by turning their gig platform data into an alternative credit score currently accepted by the largest banks of Latin America.

Bilayer Therapeutics

FUNDRAISING

Bilayer Therapeutics is developing first-in-class therapeutics for chronic constipation and other diseases of the colon, with targeted delivery achieved via a proprietary bilayer tablet.

BintanGO

FUNDRAISING

BintanGO is developing a mobile platform to help content creators with business growth and management by providing productivity and monetization tools as well as financial solutions.

Bleximo

FUNDRAISING

Bleximo is a full-stack quantum computing company focused on solving high-value optimization, simulation, and machine learning problems in different industries, which cannot be efficiently tackled by digital computers. Advantages to end users include faster, cheaper, and more precise simulations and access to more complex numerical models.

Blu Sphinx

Blu Sphinx is a digital platform that provides time-saving and cost-effective AI solutions to solve cybersecurity compliance (NIST 800-171, CMMC) for small and medium-sized businesses, using automation to turn the burden of cybersecurity into business efficiency.

Bosque Foods

Bosque Foods is a biotech company on a mission to create the most delicious whole-cut meat alternatives, grown naturally from mycelium. We are creating better-than-meat products that deliver on the entire taste experience, nutrition, and affordability without compromise.

BreachQuest

FUNDRAISING

BreachQuest is building Priori, a cybersecurity incident response platform, to minimize breach cost and downtime by providing automated instant reponse and rapid recovery.

breathe ilo

FUNDRAISING

Breathe ilo is a hardware-software combined tracker to help women tracking their menstrual cycle determine the right time to conceive and optimize their lifestyle in terms of nutrition, training, and productivity at work.

Bridgefy

FUNDRAISING

Bridgefy lets people use mobile apps without the Internet.

Bureau Identity

Bureau is developing a customer onboarding decision system that assists businesses in fraud detection and identifying and incentivizing trustworthy users.

California Cultured

FUNDRAISING

California Cultured uses cellular agriculture technology to produce sustainable and ethical chocolate. Our products will be resistant to climate change and allow customers to enjoy their favorite foods guilt-free.

Celestial Therapeutics

FUNDRAISING

Celestial Therapeutics is developing a new class of mRNA vaccines and therapeutics using its proprietary Stellar-mRNA platform to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The platform significantly reduces reactogenicity while enhancing immunogenicity for safe, effective, and durable treatment in a variety of indications.

CellChorus

FUNDRAISING

CellChorus is a dynamic single-cell analysis company that uses AI to evaluate thousands of microscopy videos in parallel, optimizing therapeutic development, manufacturing and delivery through functional assessments of the immune system.

Chainstarters

Chainstarters has built a no-code web3 platform for businesses to leverage blockchain technology without having to hire additional developers.

ChargeWheel

FUNDRAISING

ChargeWheel is building the Airbnb of public electric vehicle (EV) charging networks with integrated battery storage. Our patented fast chargers can be deployed wherever a 240 VAC connection is available allowing us to convert home driveways and apartment garages into fast public EV charging stations.

Chimera Therapeutics

FUNDRAISING

Chimera Therapeutics is a clinical-stage company developing a proprietary allogeneic treatment, mixed chimerism, that restores immune tolerance for patients suffering from more than 100 known autoimmune disorders including multiple sclerosis and type 1 diabetes.

Cirona Labs

Cirona Labs is a biotechnology company in the cannabis industry focused on developing and manufacturing specialty ingredients.

Conatix

FUNDRAISING

Conatix is developing a cybersecurity monitoring and detection system to detect fraud and corporate malware with artificial intelligence and advanced technologies.

Cordance Medical

Cordance Medical is developing a focused ultrasound platform that opens the blood-brain barrier with a simple, non-invasive 30-minute clinic procedure that enables life-extending precision medicine to patients with brain cancers making possible liquid biopsy genomics and improved drug delivery.

Corral Data

FUNDRAISING

CorralData is an all-in-one platform that allows non-technical users to connect all their data sources (e.g., CRM, E-com, ERP, etc.) and manage all key business metrics to better collaborate, derive insights, and act on their data.

Cortina Health

FUNDRAISING

Cortina Health is developing an end-to-end skincare solution for patients to democratize elite dermatology by connecting a national network of board-certified dermatologists and pharmacies with an AI-enabled teledermatology platform.

Culina Health

Culina Health is creating a tech-enabled dietitians practice to help chronic disease patients by providing access to clinical nutrition therapy and virtual nutrition coaching.

Cytosolix

FUNDRAISING

Cytosolix is developing novel derivatives of known small molecule oral oncology drugs that selectively target cancer cells via a universal biomarker of solid tumors, acidity, significantly improving efficacy.

Datanchor

FUNDRAISING

Datanchor is developing a data security solution for business users by adding encryption, access controls, and real-time tracking directly into sensitive data.

DetraPel

FUNDRAISING

DetraPel is a vertically integrated Advanced Materials manufacturer of PFAS-Free Protective Coatings. It develops revolutionary Oil & Grease Resistant coatings for Food Packaging, omniphobic repellents for Textiles & other substrates for industrial & consumer applications. DetraPel also has a D2C business thanks to its 2018 Shark Tank appearance.

DODO

FUNDRAISING

DODO, a next-generation decentralized exchange operating on a multi-chain thesis, is designed to provide efficient on-chain liquidity for web3 assets through an original Proactive Market Maker (PMM) algorithm, making it easy for everyone to issue and trade these assets.

Dreamworld

FUNDRAISING

Delivered in stunning 4K and in a ninety-degree experience. Dreamworld provides the most lightweight and affordable AR technology for entertainment and the medical industry.

ecolytiq

ecolytiq is developing a climate action infrastructure to assist financial institutions in fighting climate change by offering environmental foot-printing, personalized impact offsetting, and ESG investments to their customers.

Encora Therapeutics

FUNDRAISING

Encora is building a non-invasive, wearable, neurostimulator to eliminate tremors for the 8 million tremor patients in the US.

Enduvo

FUNDRAISING

Enduvo is a no-code XR learning platform that allows subject experts to create immersive content on any device to reduce training costs, speed delivery time, and boost learning outcomes.

Entelexo Biotherapeutics

FUNDRAISING

Entelexo is developing next-generation exosome-based therapeutics to address incurable autoimmune diseases by specifically targeting autoreactive immune cells for effective treatment with mitigated side effects.

EV Biotech

FUNDRAISING

EV Biotech creates Microbial Cell factories using cutting edge computational modeling technology to provide industry with effective production methods. This is done faster, better, and cheaper by using its EEVEE pipeline consisting of proprietary computer algorithms to evaluate millions of strategies and can precisely tailor the cell to client requirements.

Evercity

FUNDRAISING

Evercity is a SaaS blockchain-powered platform that streamlines green debt and carbon credit origination for small and medium sized enterprises by making the originations fast, low cost, transparent, and accessible.

Exavir Therapeutics

FUNDRAISING

Exavir Therapeutics develops nanomedicines for chronic disorders in virology and the central nervous system, beginning with first-in-human ultra-long-acting integrase inhibitors that have the potential to both prevent and treat HIV with only 1 dose per 6 months.

EydisBio

EydisBio discovers and develops a portfolio of highly potent and selective protein kinase inhibitors for untreated autoimmune and inflammatory diseases, beginning with rheumatoid arthritis, chronic pain, and pulmonary hyperinflation resulting from COVID-19.

Flying Ship Technologies

Flying Ship Technologies has developed a new type of unmanned, autonomous, and eco-friendly ground effect vessels that enhance access to coastlines around the world to deliver goods efficiently to tens of thousands of destinations.

Genomic Expression

FUNDRAISING

Genomic Expression developed the OneRNA® platform to detect disease, monitor conditions, and design novel RNA therapeutics using clinically validated, cloud-based, and automated RNA sequencing of a proprietary database.

GenoTwin

FUNDRAISING

GenoTwin provides advanced OMICS insights, helping users make more informed decisions regarding infectious disease prevention, emergence, and treatment.

GridMatrix

GridMatrix’s cloud-based software handles urban traffic congestion, accidents, and emissions for cities globally with an AI-empowered traffic analytics technology.

H Quest

FUNDRAISING

H Quest developed an efficient methane pyrolysis platform for point-of-use decarbonization of natural gas. Our equipment provides zero-CO2 hydrogen to displace natural gas with no increase in cost thanks to the intrinsic sequestration of carbon in the form of a high-value co-product.

Haystack Oncology

Haystack Oncology evaluates circulating tumor DNA with ultrasensitive next-generation sequencing to identify residual, recurrent, and resistant disease in cancer patients, providing best-in-class personalized testing that prompts proactive clinical interventions to dramatically improve patient outcomes.

HDAX Therapeutics

HDAX Therapeutics utilizes a targeted platform to discover and develop safe and efficacious therapeutics for HDAC-driven pathologies including brain cancers, neuropathies and neurodegenerative disorders, improving binding and pharmacokinetic profiles while reducing off-target toxicity compared to conventional drugs.

Health Cost IQ

Health Cost IQ provides a SaaS platform to reduce employers' health costs by identifying avoidable inefficiencies, wasteful spending, and fraud with smart algorithms and predictive models.

HPC-AI Technology

HPC-AI Technology is building an open-source system, Colossal-AI, to make cutting-edge AI accessible for researchers and engineers by enabling complex AI systems to run faster and cheaper without losing accuracy on low-end GPUs.

Immunyx Pharma

FUNDRAISING

Immunyx has developed targeted neutrophil nanoparticles (TENNs) to solve the major hurdles in treating neutrophils in disease, with a focus on therapies for colitis and cancer.

imvaria

imvaria provides digital biomarker solutions driven by artificial intelligence to solve challenging diagnostic problems in serious and rare diseases for clinicians, providing financial value to payers and better diagnostic tools for patients and clinicians.

IndyGeneUS AI

FUNDRAISING

IndyGeneUS AI is a genomics company creating a block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention and detection, drug discovery and development, and precision health equity.

Inherent Biosciences

FUNDRAISING

Inherent Biosciences uses a next-generation sequencing and AI platform to commercialize epigenetic biomarkers for human complex disease, beginning with male infertility.

Interface Biosciences

FUNDRAISING

Interface Biosciences is a platform therapeutics company mining the novel chemical space of the gut microbiome to develop drugs to treat inflammatory diseases.

iQure Pharma

FUNDRAISING

iQure Pharma treats neuropathic and chronic, severe pain without the use of opioids, developing breakthrough therapeutics with a novel mechanism of action to provide more efficacious and safer treatment to hundreds of millions of patients worldwide (~35M US).

Isla Technologies

FUNDRAISING

Isla Technologies is developing an intravascular cellular implant to deliver insulin to patients suffering from type 1 diabetes, providing precise blood glucose control and eliminating the need for insulin injections.

JelikaLite

FUNDRAISING

JelikaLite is developing an innovative solution to reduce a child's autism symptoms, enabling better integration into society and improving family's quality of life. Our intelligent wearable medical device provides non-invasive brain stimulation, reducing brain inflammation, improving language skills, and reducing anxiety.

Level 42 AI

FUNDRAISING

Level 42 AI patented sensors harvest novel data unobserved, discarded, or ignored as "noise" for AI interpretation to transition from "sick" to "proactive" health care by providing fast, easy and affordable earlier disease screening and diagnostics.

Lime Therapeutics

FUNDRAISING

Lime Therapeutics is a Memorial Sloan Kettering Cancer Center spinout using a proprietary nanotechnology drug discovery platform to create a novel class of therapeutics targeting lipid metabolism in cancer and neurodegenerative disorders.

Lumirithmic

FUNDRAISING

Lumirithmic is a developer of leading 3D scanning and capture technology at scale for industries including entertainment, beautytech, video games, Metaverse, and more. Our SaaS solution is delivered using desktop, tablet, and phone products scalable to a billion people.

Lumos

FUNDRAISING

Lumos is developing a patented circadian clock adjustment system to solve poor sleep and workplace fatigue giving users restorative sleep and prime performance wherever they go and whenever they need it.

MarPam Pharma

FUNDRAISING

MarPam Pharma is developing a revolutionary one-time HIV treatment that equips a patient's own immune cells with the ability to seek out and destroy HIV where it hides, thus eliminating the burdensome need for daily medications.

MarsCharge

FUNDRAISING

MarsCharge builds advanced electric vehicle (EV) chargers that seamlessly integrate intelligent battery storage with the goal of eliminating 'Range Anxiety' for EV drivers. These chargers require less electrical infrastructure and balance the needs of market stakeholders allowing for wider fast-charging coverage, reduced costs, increased profitability, and improved electrical grid resiliency.

Matricelf

Matricelf is developing a platform for the production and printing of functioning 3D autologous tissues (cells and matrix) for a variety of medical conditions, with an initial application in spinal cord injury.

Maxwell Biosciences

FUNDRAISING

Maxwell Biosciences develops a breakthrough “one drug for many bugs” platform that targets the unchanging cell membrane, ensuring resulting therapeutics are highly potent, safe and effective against all strains/mutations of enveloped viruses (pan-coronavirus, pan-influenza, etc.), drug resistant bacteria, fungi, yeast and biofilms.

METAseismic

FUNDRAISING

METAseismic creates ultra-compact sustainable metamaterials for high-performance vibration and impact absorption, with applications in the data center, aerospace, and building industries.

MindRank

MindRank is developing an AI-enabled platform that discovers and develops next generation precision medicines, cutting the time and cost of small molecule preclinical drug discovery by 70% for biopharma customers.

myNEO

FUNDRAISING

myNEO is developing personalized cancer vaccines designed using genomic tumor fingerprints, which teach the body's defences to recognize tumor neoantigens, eliminate related cancer cells, and prevent metastasis.

Myosin Therapeutics

FUNDRAISING

Myosin Therapeutics is an oncology platform company based on the untapped, druggable superfamily of molecular nanomotors with a preclinical asset.

Nano PharmaSolutions

FUNDRAISING

Nano PharmaSolutions improves the solubility of small molecule drugs using a proprietary nanoparticle platform, enhancing the bioavailability of existing therapeutics for biopharmaceutical customers.

Natrion

Natrion develops a plug-and-play solid-state electrolyte for Li-ion batteries to mitigate fire risk, improve durability and enable the use of new high energy capacity chemistries while able to be directly implemented into existing OEM production lines for electric mobility and defense applications.

NTherma

FUNDRAISING

NTherma Corporation has invented a production technology to affordably manufacture a high-purity, structurally-precise, nanomaterial additive that enables manufacturers of lithiumion batteries the ability to offer customers game-changing product improvements to density, charge-rates, safety, and cycle-life.

Oblivious

FUNDRAISING

Oblivious offers easy-to-use tools for developers from organizations that need to process sensitive data and collaborate internally or externally without revealing private information.

Ommo Technologies

FUNDRAISING

Ommo provides accessible, cost-effective, and high-precision Six Degrees of Freedom (6DOF) tracking system that can be effectively deployed and scaled for multi-sensor applications across different industries. Its current focus is in the healthcare industry in the surgical navigation & intervention sector.

OncoPrecision

OncoPrecision is developing Patient Micro-Avatars (PMAs) to replicate cancer patients' disease for ex-vivo screening to improve therapeutic response and drug development.

OPTT Health

FUNDRAISING

OPTT is a B2B SaaS digital mental health platform that reduces therapy costs for patients and increases care capacity and personnel efficiency for healthcare organizations.

Pagedip

FUNDRAISING

Pagedip empowers enterprise marketing and enablement teams to improve sales collateral effectiveness by using a proprietary Document Engagement Index that tracks the reader's journey to improve conversion rate performance and accelerate deals through increased visibility.

Pandorum International

FUNDRAISING

Pandorum International utilizes a tissue engineering platform based in multi-omics computational biology, 3D printing, and exosome engineering to restore healthy function to diseased tissues, with pre-clinically validated indications in the cornea (blindness), lung (respiratory distress syndrome), and liver (non-alcoholic Steatohepatitis).

Pannex Therapeutics

FUNDRAISING

Pannex Therapeutics develops a platform of novel drugs that have demonstrated the ability to treat chronic pain and opioid addiction, with additional applications in several cancer types and multiple sclerosis.

Phinomics

FUNDRAISING

Phinomics has pioneered a universal “stage zero” diagnostic by isolating and sequencing the “circulome”, uncovering previously hidden circular DNA signatures that are early markers of genetic and environmental change for many cancer types, beginning with urologic cancer.

PlantSwitch

FUNDRAISING

PlantSwitch is disrupting the plastic industry by making plastic from plants instead of petroleum.

Polaris Genomics

FUNDRAISING

Polaris Genomics is a precision mental health company that is advancing the diagnosis and treatment of mental health conditions, such as PTSD, using a custom 1000-gene neuropsychiatric panel (TruGen-1) with an AI/ML bioinformatics engine (TruNorth).

Portcast

FUNDRAISING

Portcast improves supply chain profitability by accurately predicting container arrival times and forecasting cargo demand in real-time with advanced data sets and proprietary machine learning.

Protabit

FUNDRAISING

Protabit has developed an AI-based protein engineering platform that optimizes the properties of antibodies and therapeutic proteins for the pharmaceutical and biotech industries, with applications in COVID-19 and oncology.

Protai

Protai leverages AI and proteomics to develop therapeutics based on the identification of post-translational modifications and protein-protein interactions, accurately predicting targets and responses for overcoming drug resistance.

Qidni Labs

FUNDRAISING

Qidni Labs is offering the world's most accessible and cost-effective dialysis technology for millions of patients with kidney failure, through the development of a portable and waterless dialysis system.

QurCan Therapeutics

FUNDRAISING

QurCan Therapeutics developed the TERP lipid nanoparticle platform to overcome drug delivery challenges including immunogenicity, low stability, rapid clearance, and liver accumulation for patients with cancers or central nervous system diseases, enhancing the safety and effectiveness of therapeutics.

RenBio

FUNDRAISING

RenBio delivers DNA therapeutics that allow for the in vivo bioproduction of antibody and protein therapeutics, fundamentally changing the use and global reach of antibody and protein therapies by overcoming prior limitations in administration, duration of efficacy, dosing frequency, and cost.

Reveal Pharma

Reveal Pharma is a clinical-stage specialty pharma company poised to transform medical insight with safer, gadolinium-free MRI contrast agents and unparalleled targeted imaging of fibrogenesis; benefiting tens of millions of patients, accelerating development of therapeutics, and positively impacting the environment.

RevivBio

FUNDRAISING

RevivBio leverages next-generation technologies to efficiently and systematically mine the vast evolutionary space of microbiomes and bio-molecules to develop breakthrough products for high-value applications across multiple industries.

ROCSOLE

FUNDRAISING

ROCSOLE electrical tomography solutions solves the lack of industrial process level and solid detection for energy production and manufacturing processing companies. We provide actionable insights in real-time to improve energy efficiency, uptime, and eliminate run-to failures.

Sachi Bioworks

FUNDRAISING

Sachi Bioworks developed the revolutionary AI-powered Nanoligomer™ platform for high-throughput drug discovery, design, development, and validation in order to create first-in-class therapeutic assets for space medicine and personalized medicine.

SageMedic

FUNDRAISING

SageMedic accurately predicts the most effective treatment strategy for cancer patients within 1 week by screening a wide range of therapeutics against 3D microtumors derived from the patient’s live tumor sample to mimic its microenvironment and heterogeneity.

Seek AI

FUNDRAISING

Seek AI provides a collaborative data science platform that streamlines the process of working with data using natural language processing technology.

Shabodi

Shabodi has developed a platform that helps Enterprises, System Integrators, and Service Providers build and deploy next-generation applications on advanced networks such as 5G.

siRNAgen Therapeutics

FUNDRAISING

siRNAgen developed a proprietary siRNA platform that enables extrahepatic delivery to previously inaccessible organs, such as the brain and lung, to develop breakthrough therapeutics for chronic diseases with high unmet needs as well as cosmetics for hair-loss.

Sisu Pharma

FUNDRAISING

Sisu Pharma is a precision oncology company that exploits cellular stress to develop highly selective HSF1 protein degraders for treating advanced and metastatic cancers such as prostate, breast and lung.

SKYHOOK SOLAR

Skyhook Solar has created the Skyhook Solar Station, a modular, movable electric vehicle (EV), and micro mobility charge product ready for any location. We are first-to-market and make micro mobility both profitable and sustainable by providing zero-emissions solar power and large-capacity battery storage while eliminating sunk costs of construction and permitting.

SlyceData

FUNDRAISING

SlyceData provides financial data management software to automate the process of ingesting, mapping, querying, and accessing data for investment researchers across multiple financial datasources, reducing the time and cost of data management and driving alpha discovery for their clients.

Solaires Entreprises

FUNDRAISING

Solaires has developed a patent-pending perovskite Solar InkTM that replaces silicon in solar cells to help manufacturers meet market demands for applications that require flexible solar cells. Unlike silicon, perovskite solar cells are flexible, lighter, can generate up to 2x times more power, and provide a greater range of applications.

SPARK Neuro

FUNDRAISING

SPARK Neuro provides objective and accessible diagnosis and monitoring of central nervous system disorders, including Alzheimer's disease, for better clinical care and drug discovery, addressing an unmet need for doctors, pharmaceutical companies, and patients.

Spiral Technology

FUNDRAISING

Spiral Technology makes AI-based Augmented Reality platforms that increase the speed and accuracy of knowledge-capture of complex manufacturing processes, training of new technicians, validation of correct procedures, and industrial quality inspections.

Steg.AI

FUNDRAISING

Steg.AI develops B2B SaaS forensic watermarking software to solve multimedia leak-protection for consumer-facing companies, providing increased sales revenue via greater information security.

Strong Network

Strong Network delivers a multi-cloud platform to solve the IT efficiency and security problem of a distributed and externalized code development process by providing IT cost reduction, devops automation, leak prevention, and real-time process governance metrics.

Sundial Foods

Sundial Foods uses a proprietary structuring technology to increase the complexity of plant-based meat textures that can create whole cuts of plant-based meat complete with skin, muscle, and bone.

Sunthetics

FUNDRAISING

Sunthetics is democratizing the use of AI in the chemical industry with a platform that enables the development of new chemical products, processes, and formulations up to five times faster, using small data.

syGlass

syGlass enables virtual reality direct volume rendering of CT, MRI, and 3D microscopy, enabling scientists, medical practitioners, and students to explore, annotate, and communicate around a new paradigm of real science data.

Terecircuits

Terecircuits develops advanced material solutions that are easily integrated into current semiconductor manufacturing processes to increase yield and throughput while reducing cost. Our technology supports heterogeneous assembly of small, fragile, and thinned components, Chiplets, sensors, power devices, and passives. Our process is ideal for achieving scale with reduced waste.

Think Bioscience

FUNDRAISING

Think Bioscience engineers microbes to access novel chemistries for elusive drug targets.

TRIPP

TRIPP is building a self-directed, fully immersive XR platform to help individuals seeking personal transformation or assistance with mental health issues by designing and curating neuroscientific-based digital wellness psychedelic experiences.

Troverlo

FUNDRAISING

Troverlo is developing a low-cost asset tracking technology that can follow, locate, and retrieve insights on any asset using a standard Wi-Fi chip as an asset tag.

Truffle Health

Truffle Health saves patients and employers money on medical care by detecting and correcting errors, overcharges, and fraud on medical bills.

Turion Space

FUNDRAISING

Turion Space is building and operating satellites to gather space-situational-awareness data and will provide space logistics services, including in-orbit transportation and orbital debris removal to ensure a sustainable future in space.

UbiquiTx

FUNDRAISING

UbiquiTx utilizes a deep learning AI/ML platform to develop a novel class of mRNA therapeutics that selectively degrade historically undruggable targets, including post-translational proteins and initially targeting transcription factors that suppress the immune response.

Unum ID

Unum ID is the ID card network, powering digital ID cards that allow companies to instantly verify identity online with full user consent.

Veracity Protocol

FUNDRAISING

Veracity Protocol is building a protocol of trust for physical objects to allow authentication, identification, and tokenization of physical assets non-invasively for B2B customers across many industries and web3.

Vici Robotics

Vici's mobile robots automate in-store labor hours by stocking shelves and picking e-commerce orders. Our robots mechanize the most significant labor expense in retail by picking up, transporting, and placing a wide variety of products.

Waypoint Bio

Waypoint Bio visualizes spatial biology to power AI-designed cell therapies.

Webee

FUNDRAISING

Webee provides a 360 degree asset intelligence platform designed to reduce costs, increase throughput, and eliminate unplanned downtime in industrial manufacturing and agriculture.

Wild Biotech

Wild Biotech has created an end-to-end drug discovery & development platform, translating the super-hero features of wild animals' untapped gut microbiomes into a new class of oral biologics for human diseases.

Woven Orthopedic Technologies

FUNDRAISING

Woven Orthopedics Technologies developed a patented and clinically proven Ogmend® sleeve, which serves as a first-in-class device for orthopedic surgeons to increase implant fixation strength and promote bony ingrowth for optimal healing in compromised fixation scenarios.

XGenomes

FUNDRAISING

XGenomes has developed a DNA sequencing platform with sample preparation that enables up to 100x improvement in the sensitivity, accuracy and speed of current methods, expediting the translation of genomic data into clinical medicine.

Xinterra

Xinterra radically accelerates the development and application of materials to meet the urgent challenges of the climate crisis, using a unique combination of Artificial Intelligence systems, High Throughput Experimentation tools and deep Material Science expertise.

ZaiNar

ZaiNar is developing a real-time, automatic, 3D location tracking platform for phones, vehicles, drones, IoT, and physical assets using signals these devices emit during normal operations with sub-meter accuracy.

Zoundream

FUNDRAISING

Zoundream is creating an acoustic interpreter that translates real-time baby cries into actual meaning and identifies potential pathologies and development disorders with cutting edge sound recognition technology.